University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 21 of 35

COMPLETED NA

Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial

NCT02966054

COMPLETED NA

Comparing Treatment of Urolithiasis Between Disposable and Reusable Ureteroscope

NCT03040466

COMPLETED

Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing

NCT01849653

COMPLETED NA

Decreasing Over Screening and Treatment of Cervical Precancers in Young Women

NCT02270021

TERMINATED Phase 1

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

NCT02116959

COMPLETED Phase 1

Cocaine Opioid Oxytocin Option - Limited

NCT02028533

COMPLETED NA

Online Positive Emotion Skills Intervention for Symptoms of Depression

NCT01964820

COMPLETED

Prospective Research of Outcomes After Salpingo-oophorectomy

NCT01948609

TERMINATED NA

Independent Exercise Compared With Formal Rehabilitation Following Primary Total Knee Replacement

NCT01826305

TERMINATED NA

Enhancing Motivation in Recent Onset Schizophrenia

NCT01817387

TERMINATED NA

Examining the Effects of Diet on Health in Prediabetes With an Online Program

NCT02188823

TERMINATED Phase 1

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

NCT02177773

TERMINATED Phase 2

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062

COMPLETED NA

The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

NCT02096757

TERMINATED NA

ODEN Trial: Option vs. Denali IVC Filters

NCT02201277

COMPLETED NA

Decisional Quality for Patients With Coronary Artery Disease

NCT02145481

COMPLETED Phase 1

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846

COMPLETED NA

Optimizing Resilience and Coping in HIV Via Internet Delivery

NCT01997008

COMPLETED NA

DuoPACT Pilot Intervention

NCT02181881

COMPLETED Early Phase 1

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

NCT01748149

COMPLETED Phase 2

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

NCT01804465

COMPLETED NA

Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers

NCT02122068

COMPLETED NA

Pilot of Social Network Intrauterine Contraceptive (IUC) Intervention

NCT01965743

COMPLETED Phase 4

Glucagon Use in Colonoscopies

NCT02078726

COMPLETED NA

Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment

NCT02125942

COMPLETED NA

A Family-Based Approach To Reduce Smoking in Vietnamese Men

NCT02007707

TERMINATED Phase 2

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

NCT02023905

COMPLETED

Transforming Research and Clinical Knowledge in Traumatic Brain Injury

NCT02119182

COMPLETED Phase 1

Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation

NCT02088931

COMPLETED

Therapeutic Resources for Attention Improvement With Neuroimaging for TBI

NCT02082509

COMPLETED Phase 2

The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II

NCT01979874

COMPLETED NA

Comparison of Treatment for Hoarding Disorder

NCT02040805

COMPLETED NA

Patient-Centered Care and Asian Americans

NCT02139722

COMPLETED

Gardasil Immunogenicity With Needle-Free Injection

NCT01924754

COMPLETED Phase 2

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

NCT02040298

COMPLETED NA

UCSF TARA Study: Training for Awareness, Resilience and Action

NCT02480257

COMPLETED Phase 2

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

NCT02023918

COMPLETED NA

Text Messaging and Cognitive Behavioral Therapy for Depression

NCT01083628

COMPLETED Phase 2

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT01781975

COMPLETED NA

Fitness, Cellular Aging, and Caregiver Stress Study

NCT01993082

COMPLETED NA

Endoscopic Surgery for Bariatric Revision After Weight Loss Failure

NCT01871896

COMPLETED Phase 1

HomeTech Healthy Lifestyle Program for Mothers With Young Children

NCT01819987

TERMINATED

Butterfly Sensor With Rev K Version

NCT01992003

COMPLETED Phase 2

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus

NCT01958320

COMPLETED NA

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

NCT01982968

COMPLETED NA

Community-Based Cognitive Training in Early Schizophrenia

NCT01973270

COMPLETED NA

Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products

NCT01964807

COMPLETED

Cognitive Effects of Anesthesia on Children

NCT02005185

COMPLETED Phase 1

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

NCT01971814

COMPLETED NA

Chronic Effects of DBS in Parkinson's Disease and Dystonia

NCT01934296

← Previous Page 21 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.